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ABSTRACT 
The aim of this study was to evaluate the outcomes of trabeculectomy with mitomycin C (MMC) in patients with 
Pseudoexfoliative Glaucoma (PXG) and compare the results with the outcomes of trabeculectomy without MMC in 
PXG and with MMC in Primary Open Angle Glaucoma (POAG). Ninety eyes (76 patients) submitted to trabeculectomy 
were included in a one-year retrospective study. Fifty-eight eyes with PXG were divided into group 1 (28 eyes) and 
group 2 (30 eyes), with and without MMC application respectively. Then, the group 1 results were compared with 32 
eyes with POAG that performed trabeculectomy with MMC (group 3). Main outcome measures were intraocular 
pressure (IOP), number of IOP lowering medications, rate of bleb failure (encapsulation, flattening and/or 
vascularization) and the number of eyes submitted to surgical procedures after trabeculectomy (needling, 5-
fluorouracil (5FU) or 2nd trabeculectomy). Results revealed that compared to trabeculectomy with MMC in POAG and 
trabeculectomy with MMC in PXG, trabeculectomy without MMC in PXG leads to higher IOP (preoperative mean ± 
standard deviation [SD] was 28.6 ± 5.4 mmHg in group 1, 32.2 ± 8.2 mmHg in group 2 and 26.1 ± 6.5 mmHg in group 3; 
and after one year was 13.9 ± 3.9 mmHg in group 1, 16.1 ± 5.9 mmHg in group 2 and 12.5 ± 4.0 mmHg in group 3); higher 
number of IOP lowering medications (preoperative mean ± SD was 3.1 ± 0.60 in group 1, 2.8 ± 0.81 in group 2 and 3.4 ± 
0.76 in group 3; and after one year was 1.1 ± 1.1 in group 1, 1.1 ± 1.0 in group 2 and 0.33 ± 0.89 in group 3); higher 
prevalence of bleb failure (47% in group 1, 53% in group 2, and 18% in group 3); and increased participation in surgical 
procedures following trabeculectomy (47% in group 1, 57% in group 2, and 6% in group 3). We concluded that 
trabeculectomy without MMC in PXG had the worst surgical outcome. Thus, PXG appears to be a potential risk factor 
for filtration bleb failure. Therefore, it could be considered in surgical protocols of MMC application. 
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INTRODUCTION
Pseudoexfoliative glaucoma (PXG) is the most usual form 
of secondary open-angle glaucoma, which develops as a 
result of pseudoexfoliative syndrome (PXS), a systemic 
circumstance characterized by abnormal production and 
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accumulation of extracellular elastin-related 
microfibrillar materials within the anterior segment of 
the eye (including the lens capsule, ciliary body, iris, 
zonules and trabecular meshwork) and other organs such 
as the heart, lungs and kidneys. In contrast to primary 
open angle glaucoma (POAG), it has a more aggressive 
clinical course with higher mean intraocular pressure 
(IOP), peak IOP, wider IOP fluctuation, as well as severe 
visual field damage and greater optic disc damage at 
diagnosis, faster rates of progression with more rapid 
visual field deterioration, worse response to medical 
therapy and greater need of surgical intervention [1-6]. 
Both genetic and environmental factors seem to show a 
role in PXS pathogenesis, and specifically, it has been 
associated with polymorphisms in the lysyl oxidase-like 
protein 1 (LOXL1) gene, an important gene for elastin 
metabolism. The main mechanisms of glaucoma in PXS 
are the blockage of the trabecular meshwork by 
exogenous and endogenous exfoliation materials and 
trabecular meshwork dysfunction. Moreover, the 
following factors are well-documented characteristics of 
PXS eyes and possible triggering factors of the abnormal 
matrix process in tissue of the anterior segment in PXS: 
increased oxidative stress conditions, a pronounced 
anterior chamber hypoxia, elevated homocysteine levels, 
increased transforming growth factor beta (TGF-β) and 
endothelin-1 levels in aqueous and a transient 
upregulation of proinflammatory cytokines such as 
interleukin (IL)-6 and IL-8. PXG has also been reported to 
be associated with more severe destruction of the blood-
aqueous barrier after trabeculectomy than POAG, as well 
as with iris vasculopathy and systemic vascular diseases. 
These changes contribute to a greater inflammation 
profile and probably affect surgical outcomes after 
trabeculectomy [1-9]. 
Trabeculectomy has become the gold standard of 
glaucoma surgery since its presentation in 1967 [10]. 
Nevertheless, long-term cumulative failure rates of 
trabeculectomy are associated with progressive fibrosis 
at the episcleral-conjunctival interface with bleb scarring. 
Adjunctive antimetabolites, such as 5-fluorouracil (5FU) 
and mitomycin C (MMC), are commonly used to enhance 
success after trabeculectomy, and its benefits have been 
demonstrated in several clinical trials, as they reduce 
subepithelial fibrosis [10-14]. The MMC is a potent non-
specific alkylating agent whose active metabolite would 
crosslink DNA molecules and thereby inhibit DNA 
synthesis, acting on fibroblasts and endothelial cells [10-
14]. However, there is still no standard protocol 
regarding the dose and duration of MMC application 
during trabeculectomy, as well as controversy regarding 
the delivery vehicle and the size or shape of the sponge 
[10, 15-17]. 
The authors decided to evaluate the outcomes of 
trabeculectomy with MMC in PXG and compare the 
results with the outcomes of trabeculectomy without 
MMC in PXG and with MMC in POAG. The aim was to 
analyze the PXG as a risk factor for trabeculectomy 
failure.  
METHODS 
The surgical technique applied was the modified 
trabeculectomy of the Moorfields Safer Surgery System 
(MSS), developed by Peng Khaw and colleagues in 2005. 
The choice of MMC was stratified according to risk 
factors for surgical failure, and to achieve this purpose 
we applied MMC according to the Moorfields Eye 
Hospital/Florida University Risk Classification and the 
European Glaucoma Society (EGS) Guidelines (Tables 1 
and 2) [14,18]. Accordingly, and to better compare the 
groups, all the patients were included in the same group 
risk (high group risk) submitted to the same dose and 
duration of MMC, and as such were submitted to the 
application of MMC at a dose of 0.4 mg/mL for 3 
minutes, immediately followed by profuse washing of the 
contact surface with saline solution. 
Ninety eyes of 76 patients undergone modified 
trabeculectomy (MSS) from January 2014 to March 2018 
were included in a retrospective study with a 12-month 
follow-up, performed at a tertiary single-center 
(Department of Ophthalmology, Professor Doutor 
Fernando Fonseca Hospital, Lisbon, Portugal). Exclusion 
criteria were any type of glaucoma other than POAG and 
PXG, aphakia, history of corneal or retinal surgery with a 
conjunctival approach and follow-up episode not totaling 
12 months. The eyes were allocated to three groups (Fig 
1) – group 1 (28 PXG eyes with MMC application), group 
2 (30 PXG eyes without MMC application) and group 3 
(32 POAG eyes with MMC application). The same 
experienced surgeon performed all surgeries. Main 
outcome measures were IOP, the number of anti-
glaucomatous medications (active principles), rate of 
bleb failure (encapsulation, flattening and/or 
vascularization) and the number of eyes submitted to 
surgical procedures after trabeculectomy (needling, 5FU 
or second trabeculectomy). The patients were observed 
preoperatively and 1, 3, 6 and 12 months 
postoperatively. 
The study had two phases (Fig 1): in the first one, group 1 
was compared with group 2 (PXG groups), and in the 
second phase group 1 was compared with group 3 (MMC 
groups). Data was collected from each patient’s medical 
records. This study followed the tenets of the Declaration 
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of Helsinki. Ethical approval received from a related 
academic institution and all patients signed a written 
informed consent after a detailed explanation of the 
study. Statistical analysis was performed with SPSS 22.0 
software (SPSS Inc., Chicago, Illinois, USA). Results were 
considered statistically significant if the p-value was 
equal to or less than 0.05. Statistical tests applied were T-
Student, Chi-Square, Shapiro-Wilk, Wilcoxon and Mann-
Whitney. 
 
Table 1. Moorfields Eye Hospital/Florida University Risk Classification. Abbreviations: 5FU: 5-fluorouracil; MMC: Mitomycin C; mg: milligram; mL: 
milliliter [14,18]. 
Low risk Moderate risk High risk 
Nothing or 5FU 50mg/mL in 5 minutes 5FU 50 mg/mL in 5 minutes or MMC 0.2 mg/mL in 3 
minutes 
MMC 0.4 mg/mL in 3 minutes 
Without risk factors Topic therapy (epinephrine) Neovascular glaucoma 
Topic therapy (β-antagonists or pilocarpine) Previous cataract surgery (without conjunctival incision 
and capsule rupture) 
Chronic persistent uveitis 
Young (< 40 years) without other risk factors Several low-risk factors Previous trabeculectomy failure 
Black elderly Phacotrabeculectomy Chronic conjunctival inflammation 
- Previous conjunctival surgery (as in strabismus, retinal 
detachment, and trabeculectomy) 
Multiple risk factors 
-  Aphakic glaucoma 
 
Table 2. European Glaucoma Society (EGS) Guidelines for Risk Factors 
for Trabeculectomy Failure. Abbreviations: Afro-Caribbean race: 
African-Caribbean race  [14,18]. 
Neovascular glaucoma 
Previous trabeculectomy failure 
Former cataract surgery with the conjunctival incision 
Aphakia (intracapsular cataract surgery) 
Current surgery (< 3months) 
Inflammatory ocular disease 
Hispanic or Afro-Caribbean race 
Young age 
Long term use of topical medication 
 
Figure 1. Study Design Diagram 
 
Abbreviations: PXG: Pseudoexfoliative glaucoma; MMC: mitomycin C; 
POAG: Primary open angle glaucoma. 
RESULTS 
Ninety eyes of 76 patients with mean ± standard 
deviation (SD) age of 64.0 ± 11.4 years; 40 females and 
36 males included in this study.  
PHASE I – Comparison between PXG groups (group 1 – 
with MMC, and group 2 – without MMC), Table 3: 
1. Evolution of IOP (Fig 2): mean ± SD of preoperative IOP 
was 28.6 ± 5.4 mmHg in group 1 and 32.2 ± 8.2 mmHg in 
group 2. The mean ± SD IOP at the 1st month was 14.7 ± 
5.8 mmHg (group 1) and 16.2 ± 6.8 mmHg (group 2); at 
the 3rd month 13.4 ± 4.1 mmHg (group 1) and 16.9 ± 6.4 
mmHg (group 2); at the 6th month 14.4 ± 5.3 mmHg 
(group 1) and 15.6 ± 4.3 mmHg (group 2); and at the 1st 
year 13.9 ± 3.9 mmHg (group 1) and 16.1 ± 5.9 mmHg 
(group 2). The group 1 had lower IOP values at all stages 
of follow-up, but a statistically meaningful difference of 
IOP reduction noted between the two groups only at the 
3rd month after the surgery (P = 0.04). The difference 
between preoperative IOP and at the 1st year was 
statistically significant in both groups (P = 0.001 in both). 
2. Evolution in number of medications (Fig 3): mean ± SD 
of preoperative number of medications were 3.1 ± 0.60 
(group 1) and 2.8 ± 0.81 (group 2); at the 1st month 0.47 
± 0.64 (group 1) and 0.57 ± 0.85 (group 2); at the 3rd 
month 0.79 ± 1.0 (group 1) and 0.79 ± 0.89 (group 2); at 
the 6th month 0.86 ± 1.1 (group 1) and 1.2 ± 1.1 (group 
2); and at the 1st year 1.1 ± 1.1 (group 1) and 1.1 ± 1.0 
(group 2). Group 1 had less medication through the 
follow-up and no statistically significant difference in 
medications number was found between the two groups. 
The difference between preoperative IOP and at the 1st 
year was statistically significant in both groups (p = 0.001 
in group 1 and P = 0.0017 in group 2). 
3. Bleb failure: group 1 had a lower prevalence of bleb 
failure than group 2 (47% versus 53%, p = 0.045). 
4. Additional surgical procedures performed after 
trabeculectomy: additional surgical procedures were 
performed more often in group 2 (57% versus 47%, P = 
0.04). 
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Table 3. Comparison Between Groups 1 and 2 (group 1 – PXG with 
MMC, and group 2 – PXG without MMC). 
 Group 1 
(PXG with 
MMC) 
Group 2 (PXG 
without 
MMC) 
Significance 
of the 
difference 
IOP Mean± SD Mean± SD P value 
Preoperative  28.6 ± 5.4 32.2 ± 8.2 0.102 
1st month  14.7 ± 5.8 16.2 ± 6.8 0.186 
3rd month  13.4 ± 4.1 16.9 ± 6.4 0.04 
6th month  14.4 ± 5.3 15.6 ± 4.3 0.887 
1st year 13.9 ± 3.9 16.1 ± 5.9 0.107 
Difference between 
preoperative and 1st 
year (P value) 
0.001 0.001 - 
Number of medications Mean± SD Mean± SD P value 
Preoperative  3.1 ± 0.60 2.8 ± 0.81 0.196 
1st month  0.47 ± 0.64 0.57 ± 0.85 0.544 
3rd month  0.79 ± 1.0 0.79 ± 0.89 0.59 
6th month 0.86 ± 1.1 1.2 ± 1.1 0.9 
1st year  1.1 ± 1.1 1.1 ± 1.0 0.817 
Difference between 
preoperative and 1st 
year (P value) 
0.001 0.0017 - 
Complications and 2ry 
Surgery 
Percentage 
(%) 
Percentage 
(%) 
 
Bleb failure (nbr of eyes) 47% 53% 0.045 
Needling, 5FU injection 
and 2ry trabeculectomy 
(n of eyes) 
47% 57% 0.04 
Data are presented as mean ± SD. Abbreviations: PXG: 
Pseudoexfoliative glaucoma; MMC: mitomycin C; IOP: intraocular 
pressure; 5FU: 5-fluorouracil; 2ry: secondary; n: number; SD: standard 
deviation; %: percentage; P values < 0.05 are in bold. 
 
 
Figure 2. Evolution of Intraocular Pressure (IOP) in PXG Groups (group 
1 – PXG with MMC, and group 2 – PXG without MMC). Abbreviations: 
PXG: Pseudoexfoliative glaucoma; MMC: mitomycin C. 
 
 
Figure 3. Evolution of the Number of IOP Lowering Medications in PXG 
Groups (group 1 – PXG with MMC, and group 2 – PXG without MMC). 
Abbreviations: PXG: Pseudoexfoliative glaucoma; MMC: mitomycin C. 
 
PHASE II – Comparison between MMC groups (group 1 – 
PXG, and group 3 – POAG group), Table 4:  
1. Evolution of IOP (Fig 4): in group 3, mean ± SD of IOP 
was 26.1 ± 6.5 mmHg before surgery, 11.5 ± 4.6 mmHg at 
the 1st month, 12.5 ± 5.1 mmHg at the 3rd month, 11.1 ± 
3.9 mmHg at the 6th month and 12.5 ± 4.0 mmHg at the 
1st year. Group 1 had higher IOP values at all stages of 
the follow-up, but a statistically significant difference in 
IOP reduction was found between the two groups only at 
the 6th month after surgery (P = 0.045). The difference 
between preoperative IOP and postoperative IOP at the 
1st year was statistically significant in both groups (with 
equal significance, P = 0.001). 
2. Evolution in the number of medications (Fig 5): in 
group 3 the mean ± SD of the number of medications was 
3.4 ± 0.76 before surgery, 0.24 ± 0.56 at the 1st month, 
0.38 ± 0.89 at the 3rd month, 0.21 ± 0.58 at the 6th 
month and 0.33 ± 0.89 at the 1
st
 year. Despite a slightly 
lower number of medications in the preoperative period 
(without a significant difference), group 1 had a higher 
number of medications at all stages in the postoperative 
period, with statistically significant differences at 6
th
 
month and at the 1
st
 year (P = 0.048 and P = 0.036, 
respectively). The difference between preoperative IOP 
and postoperative IOP at the 1
st
 year was statistically 
significant in the both groups (P = 0.001 in group 1 and P 
= 0.006 in group 3). 
3. Bleb failure: group 1 had a higher prevalence of bleb 
failure than group 3 (47% versus 18%, P = 0.02). 
4. Additional surgical procedures performed after 
trabeculectomy: additional surgical procedures were 
performed more often in group 1 (47% versus 6%), with a 
statistically significant difference (P = 0.013). 
 
 
 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2019; 8(2)  
 
77 TRABECULECTOMY WITH AND WITHOUT MITOMYCIN C IN PSEUDOEXFOLIATIVE GLAUCOMA 
Table 4. Comparison Between Groups 1 and 3 (group 1-PXG with MMC, and group 3-POAG with MMC) 
 Group 1 (PXG) Group 3 (POAG) Significance of the difference 
IOP Mean ± SD Mean ± SD P value 
Preoperative  28.6 ± 5.4 26.1 ± 6.5 0.175 
1st month  14.7 ± 5.8 11.5 ± 4.6 0.151 
3rd month  13.4 ± 4.0 12.5 ± 5.1 0.329 
6th month  14.4 ± 5.3 11.1 ± 3.2 0.045 
1st year 13.9 ± 3.9 12.5 ± 4.0 0.3 
Difference between preoperative and first year (P value) 0.001 0.001 - 
Number of medications Mean ± SD Mean ± SD  
Preoperative 3.07 ±  0.59 3.4 ± 0.76 0.114 
1st month 0.47 ± 0.64 0.24 ± 0.56 0.195 
3rd month 0.79 ± 0.97 0.38 ± 0.89 0.111 
6th month 0.86 ± 1.1 0.21 ± 0.58 0.048 
1st year 1.1 ± 1.1 0.33 ± 0.89 0.036 
Difference between preoperative and first year (P value) 0.001 0.006 - 
Complications and 2ry Surgery Percentage (%) Percentage (%) P value 
Bleb failure (nbr of eyes) 47% 18% 0.02 
Needling, 5FU injection and 2ry trabeculectomy (nbr of eyes) 47% 6% 0.013 
Abbreviations: PXG: Pseudoexfoliative glaucoma; POAG: Primary open angle glaucoma; IOP: intraocular pressure; 5FU: 5-fluorouracil; 2ry: secondary; nbr: 
number; SD: standard deviation; %: percentage; P values < 0.05 are in bold. 
 
 
Figure 4. Evolution of Intraocular Pressure (IOP) in MMC Groups. 
Abbreviations: PXG: Pseudoexfoliative glaucoma; MMC: mitomycin C; 
POAG: Primary open angle glaucoma. 
 
 
Figure 5. Evolution of Number of Medications in MMC Groups. 
Abbreviations: PXG: Pseudoexfoliative glaucoma; MMC: mitomycin C; 
POAG: Primary open angle glaucoma. 
DISCUSSION 
In this study, measured outcomes in the PXG group 
without MMC application were tendentially worse 
compared with the PXG group with MMC application and 
with the POAG group, supporting the hypothesis of PXG 
being a relevant risk factor for bleb failure. The 
differences between these groups are consistent with 
the fact that PXG is a more aggressive type of glaucoma, 
due to a high inflammatory profile. This profile is thought 
to contribute to a worse prognosis with higher IOP, and 
the necessity of more medication and secondary surgical 
procedures [1-6]. Therefore, surgical MMC application 
can probably improve the outcome of trabeculectomy in 
PXG patients, as it reduces episcleral–conjunctival 
fibrosis through potent antifibrotic action [10-14]. 
There are several studies about trabeculectomy 
outcomes and the potential risk factors for 
trabeculectomy failure in POAG, as well as different 
surgical protocols on MMC application, which vary in 
exposure time, MMC concentration, delivery vehicle and 
the size or shape of the sponge [1, 10, 15-17]. However, 
there is no standard protocol and there are few studies 
regarding MMC application in PXG patients [1, 10, 15-17]. 
Furthermore, not all studies comparing the outcomes of 
trabeculectomy between POAG and PXG include the 
application of MMC [1]. PXG which could be unilateral at 
presentation is not yet a standard risk factor for 
trabeculectomy failure, so that it alone justifies the 
application of MMC to reduce that risk. Most studies 
regarding the surgical trabeculectomy outcomes in PXG 
and POAG patients were not statistically different, 
reporting similar surgical outcomes in both types of 
glaucoma, contrary to theoretical expectations. The 
trabeculectomy outcomes also do not seem to differ 
between phakic or pseudophakic eyes, as well as do not 
seem to be affected by the antifibrotic applied. 
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Additionally, no surgical complications seem to be 
exclusive to PXG patients. However, most of the authors 
treat trabeculectomy with steroids for a longer duration 
of time to reduce the risk of bleb failure, considering the 
greater inflammatory profile of the PXG eyes [6, 19-23]. 
In the comparison with the POAG surgery with MMC, the 
results of our study are similar to those of Lim et al. [1] as 
the authors did not find a statistically significant 
difference between PXG and POAG groups regarding 
preoperative IOP and number of medications and both 
found a statistically significant difference in the number 
of medications at the last moment of follow-up. They 
showed similar success rates for trabeculectomy with 
MMC in PXG and POAG patients at the 1st year, but 
poorer long-term IOP control from the second 
postoperative year. Ehrnrooth et al. [24] reported that 
complete success rates (without medication) were 
significantly better in a POAG group than a PXG group, 
but this difference was not statistically significant when 
qualified success (with a single topical medication) was 
included; furthermore, they did not use any adjunctive 
antifibrotics. Also, Landers et al. [25] in a 20-year follow-
up study of trabeculectomy reported that PXG is more 
likely than other types of glaucoma to progress to 
blindness, with a statistically significant difference [1]. On 
the other hand, Landa et al. [26] reported that the 
success rate was 83.6% in a PXG group and 83.7% in a 
non-PXG group at a mean of 12.6 months after 
phacotrabeculectomy with MMC. Studies such as those 
of Jerndal et al. [21] and Popovic et al. [27] also reported 
similar results between POAG and PXG white patients.  
Therefore, this issue remains controversial. Studies have 
applied different definitions of success rate and different 
MMC protocols, making comparisons between studies 
difficult. Other parameters as the follow-up period, 
ethnic differences between patients, the genetic intra 
and inter-ethnic variance and environmental influences 
may also justify the difference of results between studies 
[1-6]. The follow-up period is an essential factor to 
consider, as surgical success rate after trabeculectomy is 
known to decline over time, as shown in the study of Lim 
et al., but several studies have reported surgical success 
rates for PXG in a relatively short follow-up period [1]. 
With respect to other parameters, the prevalence of PXS 
varies among different populations and patterns of PXS-
associated LOXL1 gene variants in Asian differ from 
whites [1, 4, 7], as shown, for example, by different 
results between the study of Lim et al., performed in 
Asian patients and the other studies mentioned, 
performed in whites. PXS is currently considered the 
single most important risk factor for the development of 
open-angle glaucoma [6, 28] and in some populations (as 
populations of the Baltic countries, the Mediterranean 
region and the Arab population), the frequency of PXS 
associated with secondary open-angle glaucoma may be 
even higher than the POAG [5, 6, 28-30]. In this context, 
it is worth noting that the current study was performed 
in a Portuguese population (belonging to the 
Mediterranean region). However, the pathogenesis of 
PXS and PXG is not completely understood, given that 
variables such as genetic risk variance and environmental 
influences remain poorly characterized [3-6]. Therefore, 
further research is essential. Some of the studies 
suggesting that the trabeculectomy outcomes in PXG are 
worse than POAG, as the current study, speculate that 
the primary cause may be the more severe destruction of 
the blood-aqueous barrier after trabeculectomy in PXG. 
This may lead to marked postoperative inflammation, 
fibrous reaction and subsequent filtering bleb scarring 
and failure [1, 5, 6]. Konstas et al. [22] reported a more 
common fibrous response after trabeculectomy in PXG 
eyes, and Nguyen et al. [31] reported more severe 
destruction of the blood-aqueous barrier in PXG eyes 
through quantification of aqueous flare in the anterior 
chamber. Another mechanism that may play an 
important role is continuous deposition of extracellular 
materials in the anterior segment of PXG eyes after 
surgery, contributing to the aqueous outflow decrease. 
Thus, the inflammatory response associated with the 
mentioned mechanisms might lead to worse 
postoperative trabeculectomy outcomes in PXG [1, 5, 6]. 
Aspects that strengthen this study are the fact that 
surgeries were performed by the same experienced 
surgeon (thus reducing interindividual surgical and 
postoperative biases); comparison with the POAG group; 
and the goal of improving clinical practice through 
discussion of a controversial issue of great clinical 
importance. Additionally, this study raises the 
importance of performing a continuous postoperative 
follow-up. This study also had some limitations, such as 
the retrospective design, the relatively small sample and 
the one-year follow-up period. Thus, we suggest future 
investigations with longer follow-up period and 
prospective design to achieve more conclusive results.  
CONCLUSIONS 
PXG may be a risk factor for filtration bleb failure and 
should be considered for inclusion in surgical protocols of 
MMC application. As PXG is considered a more 
aggressive type of glaucoma, associated with a higher 
inflammatory profile, improvement of surgical protocols 
may contribute to improved clinical practice. More 
studies, featuring a larger sample and longer follow-up 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2019; 8(2)  
 
79 TRABECULECTOMY WITH AND WITHOUT MITOMYCIN C IN PSEUDOEXFOLIATIVE GLAUCOMA 
period, are necessary to validate this hypothesis and to 
support the eventual revision of surgical protocols.  
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